Skip to main content
NVDA0.00%AAPL-0.15%GOOGL+0.59%MSFT+0.03%AMZN+0.01%TSM-1.68%SPCX+0.43%AVGO-0.97%META-0.09%TSLA+0.10%SKHY-5.20%MU+0.04%BRK-B+0.06%LLY-0.10%JPM-0.32%WMT-0.09%AMD-3.36%V-0.05%XOM+0.61%ASMLa-1.66%JNJ-0.27%INTC-5.57%MA-0.38%0700.HK-1.94%1398.HK+0.79%ORCL-5.23%ABBV+1.62%BAC-0.18%CSCO-1.82%CVX-0.50%COST-0.02%KO+0.32%LRCX-5.65%CAT-1.29%AP2d-1.55%0005.HK-0.78%AMAT-3.17%UNH-1.22%HSBA.L-1.30%DELL-5.35%PG+0.25%MS-1.22%GE-0.39%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.53%0939.HK+1.66%GS-0.88%NZDJPY-2.58%AUDJPY-1.80%CHFJPY-1.60%NZDCAD-1.45%NZDUSD-1.44%EURNZD+1.43%GBPNZD+1.39%GBPJPY-1.21%EURJPY-1.20%USDJPY-1.17%CADJPY-1.15%NZDCHF-1.02%USDZAR+0.99%USDSEK+0.98%USDNOK+0.86%AUDNZD+0.81%EURZAR+0.79%EURSEK+0.77%USDTHB+0.72%GBPZAR+0.72%AUDCAD-0.68%EURNOK+0.65%AUDUSD-0.64%AUDDKK-0.63%EURAUD+0.61%CHFSEK+0.59%USDMXN+0.58%GBPAUD+0.58%AUDSGD-0.54%USDPLN+0.49%CHFNOK+0.47%USDCHF+0.44%CADCHF+0.44%NZDSGD-0.42%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.38%GBPHKD+0.32%USDSGD+0.29%NOKJPY-0.29%GBPMXN-0.28%EURPLN+0.28%SGDJPY+0.27%EURHKD-0.21%USDDKK+0.21%AUDCHF-0.20%USDILS+0.16%NZDMXN-0.15%USDTRY+0.11%USDCNH+0.10%CHFSGD-0.09%EURSGD+0.09%PLNJPY+0.08%EURCNH-0.08%GBPCAD-0.07%EURCAD-0.05%GBPUSD-0.04%USDCOP-0.04%EURUSD-0.04%EURCZK-0.03%EURGBP+0.03%AUDNOK+0.02%GBPSGD+0.02%USDHKD+0.02%USDCAD-0.01%EURDKK+0.01%UKOIL+6.50%USOIL+6.43%XPTUSD-6.23%GAGUSD-5.47%XAGUSD-5.47%HG1-4.75%XAUUSD-1.91%GAUUSD-1.91%XNGUSD+1.68%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.33%ETHUSD-0.18%USDTUSD-0.02%XRPUSD-2.96%SOLUSD-1.53%TRXUSDT+0.12%ZECUSDT-9.23%DOGEUSD-2.23%XMRUSDT-0.01%LINKUSD-1.60%XLMUSD-1.73%BCHUSDT-9.67%LTCUSD-1.56%UNIUSD-1.38%TONUSD+24.88%HBARUSDT-1.83%SUIUSD-3.97%TAOUSDT-5.64%AAVEUSD-2.20%DOTUSDT-1.47%ICPUSDT+1.37%ONDOUSDT-3.29%WLDUSDT-2.91%ATOMUSDT-2.11%ARBUSDT-1.80%JUPUSDT-2.75%INJUSDT-2.57%STXUSDT-4.53%FETUSDT-2.39%TIAUSDT-1.13%PYTHUSDT-1.18%SEIUSDT-6.02%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.39%OPUSDT-3.00%POLUSDT-4.79%IOTAUSDT-4.19%AXSUSDT-2.25%FARTCOINUSDT-3.27%EOSUSDT-2.41%DYDXUSDT-1.79%ORDIUSDT-0.96%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%NVDA0.00%AAPL-0.15%GOOGL+0.59%MSFT+0.03%AMZN+0.01%TSM-1.68%SPCX+0.43%AVGO-0.97%META-0.09%TSLA+0.10%SKHY-5.20%MU+0.04%BRK-B+0.06%LLY-0.10%JPM-0.32%WMT-0.09%AMD-3.36%V-0.05%XOM+0.61%ASMLa-1.66%JNJ-0.27%INTC-5.57%MA-0.38%0700.HK-1.94%1398.HK+0.79%ORCL-5.23%ABBV+1.62%BAC-0.18%CSCO-1.82%CVX-0.50%COST-0.02%KO+0.32%LRCX-5.65%CAT-1.29%AP2d-1.55%0005.HK-0.78%AMAT-3.17%UNH-1.22%HSBA.L-1.30%DELL-5.35%PG+0.25%MS-1.22%GE-0.39%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.53%0939.HK+1.66%GS-0.88%NZDJPY-2.58%AUDJPY-1.80%CHFJPY-1.60%NZDCAD-1.45%NZDUSD-1.44%EURNZD+1.43%GBPNZD+1.39%GBPJPY-1.21%EURJPY-1.20%USDJPY-1.17%CADJPY-1.15%NZDCHF-1.02%USDZAR+0.99%USDSEK+0.98%USDNOK+0.86%AUDNZD+0.81%EURZAR+0.79%EURSEK+0.77%USDTHB+0.72%GBPZAR+0.72%AUDCAD-0.68%EURNOK+0.65%AUDUSD-0.64%AUDDKK-0.63%EURAUD+0.61%CHFSEK+0.59%USDMXN+0.58%GBPAUD+0.58%AUDSGD-0.54%USDPLN+0.49%CHFNOK+0.47%USDCHF+0.44%CADCHF+0.44%NZDSGD-0.42%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.38%GBPHKD+0.32%USDSGD+0.29%NOKJPY-0.29%GBPMXN-0.28%EURPLN+0.28%SGDJPY+0.27%EURHKD-0.21%USDDKK+0.21%AUDCHF-0.20%USDILS+0.16%NZDMXN-0.15%USDTRY+0.11%USDCNH+0.10%CHFSGD-0.09%EURSGD+0.09%PLNJPY+0.08%EURCNH-0.08%GBPCAD-0.07%EURCAD-0.05%GBPUSD-0.04%USDCOP-0.04%EURUSD-0.04%EURCZK-0.03%EURGBP+0.03%AUDNOK+0.02%GBPSGD+0.02%USDHKD+0.02%USDCAD-0.01%EURDKK+0.01%UKOIL+6.50%USOIL+6.43%XPTUSD-6.23%GAGUSD-5.47%XAGUSD-5.47%HG1-4.75%XAUUSD-1.91%GAUUSD-1.91%XNGUSD+1.68%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.33%ETHUSD-0.18%USDTUSD-0.02%XRPUSD-2.96%SOLUSD-1.53%TRXUSDT+0.12%ZECUSDT-9.23%DOGEUSD-2.23%XMRUSDT-0.01%LINKUSD-1.60%XLMUSD-1.73%BCHUSDT-9.67%LTCUSD-1.56%UNIUSD-1.38%TONUSD+24.88%HBARUSDT-1.83%SUIUSD-3.97%TAOUSDT-5.64%AAVEUSD-2.20%DOTUSDT-1.47%ICPUSDT+1.37%ONDOUSDT-3.29%WLDUSDT-2.91%ATOMUSDT-2.11%ARBUSDT-1.80%JUPUSDT-2.75%INJUSDT-2.57%STXUSDT-4.53%FETUSDT-2.39%TIAUSDT-1.13%PYTHUSDT-1.18%SEIUSDT-6.02%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.39%OPUSDT-3.00%POLUSDT-4.79%IOTAUSDT-4.19%AXSUSDT-2.25%FARTCOINUSDT-3.27%EOSUSDT-2.41%DYDXUSDT-1.79%ORDIUSDT-0.96%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%
IB

Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ • Healthcare

$8.14
-$0.28 (-3.4%)
Market closed

Last close at September 10, 2026 at 20:00 UTC

Open$8.31
Day Range$8.04 - $8.42
Avg. Volume (3M)14.5M
Market Cap$3.6B
52 Week Range
$1.76$9.36
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$99.3M100%
Gross Profitminus cost of goods$54.1M55%

In plain terms: out of every $100 in revenue, Iovance Biotherapeutics, Inc. currently loses $48.

Fundamentals & Financials

Revenue (TTM)
$324.9M
Net Income (TTM)
-$289.5M
EPS (TTM)
-$0.7
ROA (TTM)
-31.62%
Current Ratio
4.35
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+18.2%Q1 2026-$0.18
0.0%Q2 2026-$0.19
+17.6%Q3 2026-$0.11
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a NASDAQ-listed biotechnology company in healthcare that develops cell-based cancer immunotherapies using a patient's own immune system to target cancerous cells. In FY2025, the company recorded $263.5 million in revenue. Its lead offerings are lifileucel and LN-145, both investigational therapies in the clinical development stage.

Name
Iovance Biotherapeutics, Inc.
CEO
Frederick G. Vogt
Website
www.iovance.com
Industry
Healthcare
Year Founded
2007
Employees
975

Today's Snapshot

AI-generated

IOVA closed 3.4% lower at 8.14, in line with a weaker sector. Iovance said at a Wells Fargo investor conference that stronger sales improved its outlook.

Trading Volume

Above 10d avg 10.1M

10.4M

vs S&P 500 Today

Underperforming Market

-2.87%

Updated: September 10, 2026 at 20:21 UTC

Technical Indicators

4 Buy3 Neutral1 Sell
IOVA presents a bullish longer-term setup marked by a strong ADX that signals a defined trend and substantial positive OBV that shows volume support, while the shares remain above most medium- and long-term averages even if the very short-term moving averages are marginally higher than the current price. Momentum and oscillators are mildly constructive, and MACD is slightly positive, though intraday volatility is elevated and the stock is trading near the VWAP. Technical takeaway: Buy — strong trend and volume support coexist with a short-term pullback around intraday levels.
All signals
  • EMA (5 indicators)$4.36 - $8.34
    Buy
  • RSI (14)57.86
    Neutral
  • Stochastic %K (14, 3, 3)47.13
    Neutral
  • MACD Level (12, 26)0.69
    Neutral

Peers & Related Assets

ERASErasca, Inc.
$16.03+2.1%
MBXMBX Biosciences, Inc. Common Stock
$60.94-3.1%
VIRVir Biotechnology, Inc.
$10.58-2.1%
AVBPArriVent BioPharma, Inc.
$28.7-3.7%
MGTXMeiraGTx Holdings plc
$12.85-3.1%
REPLReplimune Group, Inc.
$13.24-8.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.